Four patents currently held, every record listed here
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2027. from the record
Of the 5 now held by other companies, 2 name Kenvue Brands LLC as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Mar 2027
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2010 to 2041.
US 11,066,358
Compositions of Essentially Pure Form IV of N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-IODO-PHENYLAMINO)-BENZAMIDE and Uses Thereof
Feb 17, 2041
US 11,453,641
Methods of Treating Neurofibromatosis with N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-BENZAMIDE
no later than Feb 17, 2041
US 12,037,306
Methods of Treating Neurofibromatosis Type 1 with N-((R))-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-BENZAMIDE
Feb 17, 2041
201620222028203420402041
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
1 pending application: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends no later than Feb 2041 · Medium confidence
Also notable
Ends no later than Mar 2027 · Low confidence
Methods of Treating Neurofibromatosis with N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-BENZAMIDE
US 11,453,641
The most cited patent in this portfolio, cited by 17 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2041. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US RE47,739
Granted 2019. Computed term ends 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Jan 2028 · High confidence
The most cited patent in this portfolio, cited by 66 later US patents, top 10% of utility patents granted in 2011 in our data. Protection runs to 2028.
now held by Kenvue Brands LLC
Also notable
Ends Apr 2028 · High confidence
Cited by 65 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by McNeil AB
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 3 terms have ended since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE47,739 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones In force · Low confidence | In force | Low confidence | |
| US 11,066,358 | Compositions of Essentially Pure Form IV of N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-IODO-PHENYLAMINO)-BENZAMIDE and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,453,641 | Methods of Treating Neurofibromatosis with N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-BENZAMIDE In force · Medium confidence | In force | Medium confidence | |
| US 12,037,306 | Methods of Treating Neurofibromatosis Type 1 with N-((R))-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-BENZAMIDE In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 4: 5 patents in force now held by others · 173 patents ended · 1 application pending · 108 applications abandoned · 1 record of undetermined status. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
15 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
30 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.